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Percutaneous coronary intervention (PCI) is performed
in more than 1 million patients worldwide each year.
Although very effective in improving the symptoms of
ischemia and quality of life, acute complications remain
the major drawback of this procedure. Studies have
demonstrated that the treated vessel closes abruptly
during or shortly after the procedure in 4–9% of cases,
causing considerable morbidity and an approximately
tenfold increase in mortality.1-4 The arterial injury that
accompanies PCI makes vascular surfaces vulnerable to
platelet deposition, aggregation, and later thrombosis.5
Platelet aggregation is inhibited by glycoprotein (GP)
IIb/IIIa inhibitors in a dose-dependent manner. More
than 80% GPIIb/IIIa receptor blockade (resulting in more
than 80% inhibition of platelet aggregation) is required to
prevent thrombus formation in a highly thrombogenic
environment.6-8 Eptifibatide (Integrilin), a GPIIb/IIIa in-
hibitor, has been approved for the treatment of patients
undergoing PCI. In this setting, eptifibatide has been
shown to decrease the rate of the combined endpoint of
death, new myocardial infarction, or the need for urgent
intervention.9 In this study, we assessed the efficacy and
safety of eptifibatide in low-risk patients undergoing PCI
who received a bolus dose sufficient to produce more
than 80% platelet inhibition that was not followed by the
continuous infusion. 
Methods
Sixty low-risk patients undergoing PCI at Huntsville
Hospital, Huntsville, AL, were included in this open-
label pilot study. Patients were excluded if they were at
high risk — that is, if they had (1) acute evolving myocar-
dial infarction within 24 hours of symptoms that necessi-
tated direct or rescue intervention, (2) unstable angina or
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Background: Abrupt closure and restenosis remain serious and costly consequences of coronary angioplasty
procedures. Eptifibatide (Integrilin) has been shown to decrease the rate of combined endpoint of death, new
myocardial infarction, or the need for urgent intervention in this setting. Platelet aggregation is inhibited by
eptifibatide in a dose-dependent manner, with more than 80% receptor occupancy required to prevent
thrombus formation. 
Objective: To evaluate the safety and efficacy of a shorter duration of treatment with eptifibatide in low-risk
patients undergoing percutaneous coronary intervention. 
Methods: We compared low-risk patients undergoing percutaneous coronary intervention who received
either conventional eptifibatide dosing or a bolus dose that was sufficient to produce more than 80% platelet
inhibition. All patients were followed for major adverse cardiovascular events (MACE) for 90 days after the
procedure. MACE complications included death, myocardial infarction (defined as elevation of the creatine
kinase-MB fraction at least 3 times the upper limit of normal or new Q-waves in 2 electrocardiographic
leads), or any treatment for recurrent angina (percutaneous transluminal coronary angioplasty, stent
placement, or coronary artery bypass grafting). Safety was assessed by the incidence of bleeding and
thrombocytopenia.
Results and Conclusions: None of the patients in either study group had a MACE or thrombocytopenia
during the follow-up period. Patients who received a conventional eptifibatide dose had a higher incidence
of minor bleeding. It appears that, in low-risk patients, a shorter duration of treatment with eptifibatide may
prevent the ischemic complications of percutaneous coronary intervention. 
J Pharm Technol 2002;18:316-8.
 at Lebanese American University on June 2, 2016pmt.sagepub.comDownloaded from 
WWW.JPHARMTECHNOL.COM NOVEMBER/DECEMBER 2002    VOLUME 18    J PHARM TECHNOL 317
a non–Q-wave myocardial infarction 24 hours prior to
procedure, or (3) angiographic characteristics indicating
high risk (type B or C lesions). Patients were also exclud-
ed if they had any contraindication for eptifibatide use or
if their serum creatinine concentrations were greater than
or equal to 2 mg/dL. 
The first group (bolus-only group) included 30 pa-
tients (23 men) aged 63.0 ± 11.4 years of age (mean ± SD).
Their platelet functions were monitored at baseline and
again 10 minutes after a bolus dose of eptifibatide 90
µg/kg, given over 1 minute, using Accumetrics Ultegra
RPFA, a point-of-care, rapid platelet function assay. Ac-
cording to this measuring technique, platelet function is
measured based on the ability of activated platelets to
bind fibrinogen.10 If less than 80% platelet inhibition was
achieved, another bolus dose of eptifibatide 90 µg/kg
was given 5 minutes after the first bolus. The second
group (bolus + infusion group) included 30 patients (20
men) aged 65.2 ± 11.6 years. This group received a bolus
dose of eptifibatide 180 µg/kg, given over 1 minute, fol-
lowed by an infusion of 2 µg/kg/min for 20–24 hours.
All patients received oral aspirin 325 mg before PCI and
daily thereafter. Oral clopidogrel was initiated (300-mg
load followed by 75 mg/d for 30 d) after coronary stent
deployment. Patients also received heparin titrated to
achieve a target activated clotting time of 200–300 sec-
onds during the procedure. 
Patients were followed for major adverse cardiovascu-
lar events (MACE) for 90 days after the procedure. MACE
complications included death, myocardial infarction
(raised creatine kinase-MB to at least 3 times the upper
limit of normal or development of Q-waves in 2 or more
contiguous leads), or any treatment for recurrent angina
(percutaneous transluminal coronary angioplasty, stent
placement, coronary artery bypass grafting). Patients
were also contacted by phone after hospital discharge to
determine whether they were hospitalized in another in-
stitution for any cardiac event.
Major safety endpoints assessed during hospitaliza-
tion were bleeding and thrombocytopenia, defined as
platelet count less than 100 × 103/mm3. Severity of bleed-
ing was classified according to the TIMI (Thrombolysis
in Myocardial Infarction) study bleeding classification.11
Using this scale, bleeding was characterized as being ei-
ther minor or major, with major bleeding defined as any
intracranial hemorrhage, a bleeding event associated
with a decrease in hemoglobin of 5 g/dL, or a decrease in
hematocrit of 15%.
Results
In the bolus-only group, 22 patients (73%) achieved
more than 80% platelet inhibition 10 minutes after ad-
ministration of the eptifibatide 90 µg/kg-bolus dose,
which did not necessitate giving another bolus dose.
None of the patients in either study group experienced a
MACE during the follow-up period. However, 2 patients
in the bolus-only group who received 1 bolus of eptifi-
batide 90 µg/kg had cardiac catheterization: 1 at 7 days
and 1 at 11 days after the PCI because of recurrent chest
pain. Catheterization laboratory reports showed that the
previous angioplasty site was widely patent in both pa-
tients, with no evidence of restenosis. The first patient
was diagnosed as having gastroesophageal reflux dis-
ease, and his chest pain improved after he was started on
a proton-pump inhibitor. The other patient was diag-
nosed as having Prinzmetal’s angina, and a calcium-
channel blocker was added to his medications, which re-
solved his symptoms.
Major bleeding was not reported in any of the patients
in either group. In the bolus-only group, 6 patients (20%)
had minor bleeding compared with 15 patients (50%) in
the bolus plus infusion group. Bleeding involved mainly
the vascular access site. Thrombocytopenia was not re-
ported in any of the patients in both groups. Although
the use of GPIIb/IIIa inhibitors has been associated with
thrombocytopenia, which in some cases can be severe, it
appears that this adverse effect occurs less frequently
with eptifibatide.12
Discussion
This trial is the first to have evaluated lower doses and
shorter duration of treatment with eptifibatide in routine,
elective coronary intervention that includes only patients
with low-risk clinical and angiographic characteristics.
The results demonstrate that the administration of eptifi-
batide at a bolus dose leading to more than 80% platelet
inhibition that is not followed by a continuous infusion
could be sufficient to prevent ischemia in low-risk pa-
tients undergoing PCI up to 90 days after the procedure.
In addition, lower doses of eptifibatide appear to be asso-
ciated with fewer bleeding complications. It may be that,
in this population, a shorter duration of treatment with
eptifibatide is sufficient because the thrombogenicity of
the disrupted artery is most likely at its highest and the
risk of abrupt vessel closure is greatest during and short-
ly after the procedure compared with an estimated 18–24
hours postprocedure in high-risk patients.13

Lower doses of eptifibatide
appear to be associated with
fewer bleeding complications.

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Summary
It appears that, in low-risk patients, a shorter duration
of treatment with eptifibatide may prevent the ischemic
complications of PCI. In addition, it appears to decrease
the risk of minor bleeding. A major limitation of this
study is that it was not sufficiently powered to provide
statistically significant clinical efficacy or safety results.
However, these results suggest that further study with a
larger population is warranted.
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